CAR T Cell Therapy in Acute Lymphoblastic Leukemia and Potential for Chronic Lymphocytic Leukemia - PubMed (original) (raw)
Review
CAR T Cell Therapy in Acute Lymphoblastic Leukemia and Potential for Chronic Lymphocytic Leukemia
Nathan Singh et al. Curr Treat Options Oncol. 2016 Jun.
Abstract
Adoptive transfer of autologous T cells engineered to express a chimeric antigen receptor (CAR) represents a powerful targeted immunotherapy that has shown great promise in some of the most refractory leukemias. CAR-modified T cells directed against CD19 have led the way, setting a high standard with remission rates as high as 90 % in clinical trials for relapsed/refractory acute lymphoblastic leukemia (ALL). Yet, the first demonstration of efficacy was in another disease, chronic lymphocytic leukemia (CLL), in which CD19-targeted CAR T cells eradicated bulky, highly refractory disease. Despite early encouraging results, clinical trials in CLL have yielded lower response rates, revealing disease-specific differences in response in this form of immunotherapy. Ongoing research focused on identifying and overcoming these limitations, promises to improve response rates. Beyond the induction of remission, the transformative impact of engineered T cell therapy lies in its potential for long-term disease control. With longer follow-up and durable T cell persistence now reported, we are closer to answering the question of whether sustained remissions are possible with CAR T cell monotherapy. As might be expected with a highly effective therapy using a single mechanism of action, escape pathways have emerged. Combinatorial approaches are needed to anticipate and prevent this mode of relapse. Lastly, toxicity management is vital to ensure the safety of this exciting cancer immunotherapy.
Keywords: Acute lymphoblastic leukemia; CD19; Cellular immunotherapy; Chimeric antigen receptor; Chronic lymphocytic leukemia; Cytokine release syndrome; Engineered T cells.
Similar articles
- The what, when and how of CAR T cell therapy for ALL.
Frey N. Frey N. Best Pract Res Clin Haematol. 2017 Sep;30(3):275-281. doi: 10.1016/j.beha.2017.07.009. Epub 2017 Aug 3. Best Pract Res Clin Haematol. 2017. PMID: 29050700 Review. - Redirecting T cells to eradicate B-cell acute lymphoblastic leukemia: bispecific T-cell engagers and chimeric antigen receptors.
Aldoss I, Bargou RC, Nagorsen D, Friberg GR, Baeuerle PA, Forman SJ. Aldoss I, et al. Leukemia. 2017 Apr;31(4):777-787. doi: 10.1038/leu.2016.391. Epub 2016 Dec 28. Leukemia. 2017. PMID: 28028314 Review. - Chimeric Antigen Receptor Therapy in Acute Lymphoblastic Leukemia Clinical Practice.
Luskin MR, DeAngelo DJ. Luskin MR, et al. Curr Hematol Malig Rep. 2017 Aug;12(4):370-379. doi: 10.1007/s11899-017-0394-x. Curr Hematol Malig Rep. 2017. PMID: 28656487 Review. - An analytical biomarker for treatment of patients with recurrent B-ALL after remission induced by infusion of anti-CD19 chimeric antigen receptor T (CAR-T) cells.
Zhang Y, Zhang W, Dai H, Wang Y, Shi F, Wang C, Guo Y, Liu Y, Chen M, Feng K, Zhang Y, Liu C, Yang Q, Li S, Han W. Zhang Y, et al. Sci China Life Sci. 2016 Apr;59(4):379-85. doi: 10.1007/s11427-016-5035-4. Epub 2016 Mar 24. Sci China Life Sci. 2016. PMID: 27009300 - Chimeric antigen receptor T-cell therapy for ALL.
Maude SL, Shpall EJ, Grupp SA. Maude SL, et al. Hematology Am Soc Hematol Educ Program. 2014 Dec 5;2014(1):559-64. doi: 10.1182/asheducation-2014.1.559. Epub 2014 Nov 18. Hematology Am Soc Hematol Educ Program. 2014. PMID: 25696911 Review.
Cited by
- The Implementation of Chimeric Antigen Receptor (CAR) T-cell Therapy in Pediatric Patients: Where Did We Come From, Where Are We Now, and Where are We Going?
Knight E T, Oluwole O, Kitko C. Knight E T, et al. Clin Hematol Int. 2024 Mar 13;6(1):96-115. doi: 10.46989/001c.94386. eCollection 2024. Clin Hematol Int. 2024. PMID: 38817691 Free PMC article. Review. - Key candidate genes and pathways in T lymphoblastic leukemia/lymphoma identified by bioinformatics and serological analyses.
Ren Y, Liang H, Huang Y, Miao Y, Li R, Qiang J, Wu L, Qi J, Li Y, Xia Y, Huang L, Wang S, Kong X, Zhou Y, Zhang Q, Zhu G. Ren Y, et al. Front Immunol. 2024 Feb 23;15:1341255. doi: 10.3389/fimmu.2024.1341255. eCollection 2024. Front Immunol. 2024. PMID: 38464517 Free PMC article. - The current landscape of CAR T-cell therapy for solid tumors: Mechanisms, research progress, challenges, and counterstrategies.
Daei Sorkhabi A, Mohamed Khosroshahi L, Sarkesh A, Mardi A, Aghebati-Maleki A, Aghebati-Maleki L, Baradaran B. Daei Sorkhabi A, et al. Front Immunol. 2023 Mar 20;14:1113882. doi: 10.3389/fimmu.2023.1113882. eCollection 2023. Front Immunol. 2023. PMID: 37020537 Free PMC article. Review. - Mesenchymal stem cell suppresses the efficacy of CAR-T toward killing lymphoma cells by modulating the microenvironment through stanniocalcin-1.
Zhang R, Liu Q, Zhou S, He H, Zhao M, Ma W. Zhang R, et al. Elife. 2023 Feb 13;12:e82934. doi: 10.7554/eLife.82934. Elife. 2023. PMID: 36779699 Free PMC article. - An Innovative PTD-IVT-mRNA Delivery Platform for CAR Immunotherapy of ErbB(+) Solid Tumor Neoplastic Cells.
Georgiou-Siafis SK, Miliotou AN, Ntenti C, Pappas IS, Papadopoulou LC. Georgiou-Siafis SK, et al. Biomedicines. 2022 Nov 10;10(11):2885. doi: 10.3390/biomedicines10112885. Biomedicines. 2022. PMID: 36359405 Free PMC article.
References
- Eur J Haematol. 2016 Jan;96(1):9-18 - PubMed
- Hum Gene Ther. 2011 Dec;22(12):1575-86 - PubMed
- Hum Gene Ther. 2013 Aug;24(8):717-27 - PubMed
- Blood. 2014 Jul 10;124(2):188-95 - PubMed
- N Engl J Med. 2014 Oct 16;371(16):1507-17 - PubMed
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Research Materials